After many years at a standstill, the entire landscape of glaucoma is changing rapidly on both the surgical side and the medical side. MIGS is now a well-established concept, new topical medications have entered the scene, and new modes of delivery are in the pipeline, some near to completion of phase 3 trials.
“It is an exciting time because we are better able to take care of our patients,” OSN Glaucoma Board Member Savak “Sev” Teymoorian, MD, MBA, said. “Patients are so unique with their disease and the way they (Read more...)
Uncategorized